Rubicon Research Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 7 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹26.0K Cr
Rubicon Research reported a strong revenue growth of 39% year-on-year in Q2 FY '26. Revenue growth of 39% year-on-year reported in Q2 FY '26, driven by new product launches and growth in existing products.
From Rubicon Research Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,725
Market Cap
₹26.0K Cr
P/E Ratio
105.5
How does Rubicon Research Ltd rank in Pharmaceuticals & Biotechnology?
Compare Rubicon Research Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Rubicon Research Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net profit ₹73 Cr.
Full financials →📊 Revenue & Sales Performance
- →Rubicon Research reported a strong revenue growth of 39% year-on-year in Q2 FY '26.
- →The company anticipates continued sustained revenue traction, with a diverse product portfolio reducing dependence on top products.
- →Growth is driven by new product launches, continued ramp-up of existing products, and expansion in branded specialty products.
- →Expansion plans include ramping up manufacturing capacity, notably the Pithampur plant expected to be operational by mid-2026 and fully contributing by early 2027.
- →Focus on regulated markets, primarily the U.S., with additional filings in rest-of-world markets, though significant revenue currently from the U.S.
- →Commercialization rate of approved products is strong at 93%, supporting ongoing growth.
- →Specialty products now account for approximately 33% of gross profit, with focus on neurology and neuro-rare therapies expected to fuel future growth.
- →Pricing remains stable due to focus on differentiated specialty products, aiding revenue sustainability.
📈 Profitability & Margins
- →Revenue growth of 39% year-on-year reported in Q2 FY '26, driven by new product launches and growth in existing products.
- →Operating EBITDA grew 53% YoY; PAT increased by 56% YoY.
- →EBITDA margins expected to sustain at current levels despite gross margin trend towards 68%, supported by revenue ramp-up and manufacturing adjustments.
- →R&D spend is projected at 10-11% of operating revenue, sustainable over the next 4-5 years, supporting pipeline and innovation.
- →Commercialization rate of approved products remains strong at 93%, aiding consistent revenue streams.
- →Specialty products contribute about 32.5% of gross profit, indicating a strong focus on high-value products.
- →Current EBITDA trajectory likely to continue, though specific forward guidance was not provided.
- →Ramp-up of manufacturing capacity (Pithampur facility) by mid-2026 expected to support future growth and margin improvement.
🏗️ Capital Expenditure Plans
💰 Fundraising & Capital Structure
- →There was no specific mention of any current or future fundraising through debt or equity in the provided transcript of Rubicon Research Limited's Q2 FY'26 earnings call.
- →The management did not disclose any plans for raising capital via debt or equity during the call.
- →Discussions focused primarily on operational performance, product pipeline, manufacturing capacity expansion, and commercial strategy.
- →Any strategic investments mentioned were related to minority stake acquisitions aligned with pipeline strategy, not fundraising.
- →Management highlighted a disciplined, ROI-driven capital allocation approach but refrained from commenting on specifics regarding financing plans.
- →They intend to disclose details around acquisitions or investments when approvals are received.
- →Overall, no immediate plans for fundraising were indicated in the transcript.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Rubicon Research Ltd Q2 FY26 results?
Rubicon Research reported a strong revenue growth of 39% year-on-year in Q2 FY '26. Revenue growth of 39% year-on-year reported in Q2 FY '26, driven by new product launches and growth in existing products.
What is Rubicon Research Ltd share price analysis?
Rubicon Research Ltd currently shows a neutral. The stock trades at a P/E of 105.5 with a market cap of ₹26,041 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rubicon Research Ltd planning capital expenditure?
Rubicon is operationalizing the Pithampur manufacturing facility by mid-2026 (May 2026), which is expected to ease current outsourcing constraints and support future revenue growth.
Keep Rubicon Research Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.